[Natalizumab in multiple sclerosis: unclear patient benefits].

Two large randomised clinical trials were published in March 2006 that evaluated the effect of natalizumab on the incidence of disease exacerbation in patients with multiple sclerosis (MS). Both trials showed that natalizumab reduces the incidence of MS exacerbations, but it is unclear whether patients ultimately benefited from treatment. It is clear that natalizumab is associated with serious adverse events, such as progressive multifocal leukoencephalopathy. Therefore, the use of natalizumab in patients with MS cannot be considered advisable at this time.
AuthorsJ P Schipper
JournalNederlands tijdschrift voor geneeskunde (Ned Tijdschr Geneeskd) Vol. 151 Issue 15 Pg. 852-5 (Apr 14 2007) ISSN: 0028-2162 [Print] Netherlands
Vernacular TitleNatalizumab bij multiple sclerose: onduidelijke baten voor de patiënt.
PMID17472115 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Natalizumab
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Evidence-Based Medicine
  • Humans
  • Leukoencephalopathy, Progressive Multifocal (chemically induced)
  • Multiple Sclerosis (drug therapy, epidemiology)
  • Natalizumab
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: